Tag: PH10

VistaGen advances fasedienol’s Phase 3 PALISADE-3 toward data in late 2025, while PALISADE-4 continues enrollment, extending its CNS innovation momentum.

Vistagen’s late-stage CNS pipeline, led by fasedienol™, shows clinical progress and strategic growth despite liquidity pressures and non-material revenue.

Discover how VistaGen's cutting-edge Pherine technology transforms treatment for anxiety, depression, and CNS disorders, promising faster, safer therapies.